Clinical Trial Update: Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia [NA]

View source ↗

Summary

An update on a clinical trial evaluating low-dose alemtuzumab for consolidation and maintenance in chronic lymphocytic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Alemtuzumab (Campath) (alemtuzumab)

Snippet

Sponsor: Tawam Hospital | Conditions: B-Cell Chronic Lymphocytic Leukemia | NA | Status: UNKNOWN